ERBB2 and breast cancer: In a HER2-positive breast cancer mouse model, the use of entinostat in combination with anti-HER2 therapy, anti-PD1, anti-CTLA4 or both ICI’s significantly improved survival compared with ICI or entinostat alone [90].